Agios Pharmaceuticals (AGIO) vs Xencor (XNCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Xencor (XNCR) has outperformed Agios Pharmaceuticals (AGIO) over the past year, gaining 88.6% versus a loss of 25.0%. Over five years, AGIO leads with a -31.3% price change compared with -36.0% for XNCR. Agios Pharmaceuticals is the larger company by market cap ($1.90 billion vs $1.83 billion), about 1.0 times the size.
Xencor converts more of its revenue into profit, with a net margin of -73.2% versus -764.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGIO | XNCR |
|---|---|---|
| Share price | $31.81 | $24.63 |
| Market cap | $1.90B | $1.83B |
| 1-day change | -0.34% | +0.53% |
| YTD return | +16.86% | +60.88% |
| 1-year return | -25.03% | +88.59% |
| 5-year return | -31.27% | -35.98% |
| EPS (TTM) | $-7.01 | $-2.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $54.03M | $125.58M |
| Revenue growth (YoY) | +48.03% | +13.65% |
| Net income (latest FY) | $-412.78M | $-91.92M |
| Gross margin | 88.26% | — |
| Operating margin | -873.87% | -141.35% |
| Net margin | -764.01% | -73.20% |
| 52-week high | $46.00 | $30.61 |
| 52-week low | $22.24 | $10.38 |
| Distance from 52-week high | -30.85% | -19.54% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +44.61% | +27.57% |
| Average volume | 1.08M | 1.32M |
| Shares outstanding | 59.70M | 74.35M |
| Employees | 539 | 260 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XNCR has outperformed AGIO by 113.6 percentage points over the past year.
- Xencor is more profitable, keeping -73.2 cents of every revenue dollar as net income versus -764.0 cents for Agios Pharmaceuticals.
- Agios Pharmaceuticals grew revenue faster in its latest fiscal year (+48.03% vs +13.65%).
About Agios Pharmaceuticals
AGIO stock →Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency.
Health Care · Biotechnology: Pharmaceutical Preparations · 539 employees
About Xencor
XNCR stock →Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees
AGIO vs XNCR FAQ
Which is bigger, Agios Pharmaceuticals or Xencor?
Agios Pharmaceuticals (AGIO) is larger, with a market capitalization of $1.90B compared with $1.83B for Xencor (XNCR).
Which stock has performed better over the past year, AGIO or XNCR?
XNCR returned +88.59% over the past 12 months, compared with -25.03% for AGIO (price return, excluding dividends). Past performance does not predict future results.
Are Agios Pharmaceuticals and Xencor in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.